Finn
DHR Life Sciences · Diagnostics · Bioprocessing · M&A compounder · Thesis updated October 25, 2026

Core growth accelerates as bioprocessing orders sustain recovery

01 Running thesis

A choppy path to recovery

Danaher is navigating a complex but improving recovery. The third quarter of 2026 provided strong validation, with core growth excluding respiratory reaching 5.5 percent. The company is leaning into a new era under CEO Julie Sawyer Montgomery, prioritizing a connected commercial strategy and heavy investments in artificial intelligence to capture more spending from its customers.

The bull case centers on the durability of the bioprocessing recovery and the potential of new technology. Bioprocessing orders grew in the mid-teens during the third quarter, easing fears from earlier shipment delays. Furthermore, a new autonomous lab and a partnership with NVIDIA give Danaher a first-mover advantage in AI-enabled research automation, which could accelerate market share gains.

The bear case focuses on persistent headwinds. Respiratory testing remains a drag on the Diagnostics segment, with 2026 revenue planned to fall to $1.5 billion. Management also noted that financial benefits from bioprocessing reshoring are pushed out to 2028 or later. This means near-term upside relies heavily on traditional pharmaceutical markets continuing their gradual recovery.

Oct 2026▲Q3 2026 earnings showed a strong 5.5 percent core growth rate excluding respiratory testing. Management announced a new connected commercial strategy and a major artificial intelligence partnership with NVIDIA.
Jul 2026→Q2 2026 presented a mixed update. Life Sciences rebounded sharply with 5.5 percent core growth, but bioprocessing faced over $100 million in resin shipment delays.
Apr 2026▲Q1 2026 gave the first major proof point for the recovery thesis. Bioprocessing equipment orders grew more than 30 percent year over year, the first positive order growth in nearly two years.
Apr 2026→The Q1 2026 filing showed a mixed business. Biotechnology grew 7.0 percent on a core sales basis, Life Sciences grew 0.5 percent, and Diagnostics fell 4.0 percent because respiratory testing was weak.
Feb 2026→The 2025 Form 10-K reset the baseline. Biotechnology finished 2025 with 6.5 percent core growth, while Life Sciences declined 1.5 percent and Diagnostics grew 1.5 percent.
Jan 2026→Management guided 2026 core revenue growth to 3 percent to 6 percent and adjusted diluted EPS to $8.35 to $8.50. The guide framed 2026 as a gradual recovery year.
Oct 2025▲Management gave an initial 2026 framework calling for 3 percent to 6 percent core revenue growth and more than 100 basis points of adjusted operating margin expansion. Danaher also used about $2 billion for share repurchases in Q3 2025.
02 Business model

Instruments create repeat sales

Danaher sells instruments, then earns repeat revenue from the supplies, tests, software, and services those instruments require. A laboratory or hospital might buy a machine once, but it continues buying consumables for years if that machine becomes part of daily operations.

The company operates under the Danaher Business System, known as DBS. This internal culture focuses on continuous improvement for quality, speed, cost, and customer service. The goal is simple: acquire or build strong science businesses, then run them better.

Under new leadership, Danaher is shifting toward a connected strategy. Instead of operating companies selling independently, the firm aims to cross-sell integrated solutions across its portfolio. This includes leveraging artificial intelligence to speed up discovery workflows for customers.

Acquisitions remain central to the strategy. While mergers and acquisitions are the preferred use of capital, Danaher will buy back shares when the return profile is attractive, as shown by a $2 billion repurchase earlier in the year.

03 Product portfolio

Tools behind labs and tests

Growth engine

Bioprocessing systems

Danaher sells filtration, manufacturing, and workflow tools used to make biologic drugs. Equipment sales returned to revenue growth in mid-2026.

Cash cow

Bioprocessing consumables

These are repeat-use supplies tied to drug production. Order volumes are accelerating despite isolated shipment delays earlier in the year.

Steady

Life Sciences instruments

Products include mass spectrometry, microscopy, and digital pathology. The portfolio now integrates AI-powered autonomous lab workflows.

Option

Genomics and gene editing consumables

Danaher sells products used in gene reading, writing, and editing. Subsidiaries like IDT and Abcam provide critical supplies for this research.

Steady

Molecular diagnostics

Cepheid's GeneXpert system runs tests for respiratory illness and other needs. Respiratory testing remains a significant financial headwind.

Cash cow

Clinical diagnostics & monitoring

Beckman Coulter analyzers and the newly acquired Masimo patient monitoring tools help hospitals diagnose disease and track patient health.

04 Business segments

Three pieces, one swing factor

Biotechnology30%modest
Life Sciences29%growing fast
Diagnostics41%modest

Segment mix uses Danaher's Q1 2026 sales by segment: Biotechnology $1.797 billion, Life Sciences $1.737 billion, and Diagnostics $2.417 billion. The mix remains stable, but Biotechnology and Life Sciences are the primary focus for recovery.

05 Risk factors

What could go wrong

Lumpy bioprocessing demand

High impact · Medium odds

Bioprocessing is recovering, but customer behavior remains unpredictable. While order growth is strong, any return to delayed shipments or paused capital spending would threaten revenue targets.

We watchQ4 bioprocessing order conversion and early 2027 guidance figures.

Respiratory testing remains soft

Medium impact · Medium odds

Diagnostics core sales continue to face pressure from respiratory testing. A mild winter season for respiratory illness will severely limit the overall segment performance.

We watchRespiratory testing volumes as the winter season officially begins.

Connected strategy execution

Medium impact · Low odds

The new commercial strategy aims to integrate sales across independent operating companies. This could disrupt the accountability and agility that made these individual businesses successful.

We watchCommentary on cross-selling metrics and any leadership turnover at the operating company level.

Trade and conflict shocks

Medium impact · Low odds

Danaher operates a global supply chain. The company has highlighted that military conflicts could disrupt logistics or raise costs, causing delays in product delivery.

We watchFreight costs, supply delays, and new regulatory warnings in future filings.
06 Quick answers

In one breath

What does Danaher actually do?

Danaher sells tools and supplies used in life science research, biologic drug manufacturing, and clinical diagnostics. Its products help scientists study disease, help drug companies make biologic medicines, and help hospitals run tests.

Why does bioprocessing matter so much for Danaher stock?

Bioprocessing is tied to the equipment and consumables used to make biologic drugs. Orders are currently growing in the mid-teens, which signals that customers are spending again after a long pause.

How is the Diagnostics segment performing?

Clinical diagnostics remain solid, and the recently acquired Masimo business is delivering steady growth. However, weak demand for respiratory testing continues to act as a drag on total segment growth.

How is Danaher using artificial intelligence?

The company recently launched an AI-powered autonomous lab and announced a computing partnership with NVIDIA. These investments aim to automate and speed up discovery workflows for scientific customers.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
October 25, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Danaher Q3 2026 earnings transcript
  2. Danaher Q2 2026 Form 10-Q
  3. Danaher Q1 2026 Form 10-Q
08 Explore the industry

Comparable Diagnostics & Research companies

Companies near Danaher Corporation in Finn's Diagnostics & Research industry ranking.

Get started with Finn today